PDGFRA and gastrointestinal stromal tumor: While secondary resistance to imatinib is rare, it typically involves one of two specific mutations: PDGFRA T674I, which has shown in vitro response to ponatinib, or PDGFRA D842V, for which avapritinib, approved for gastrointestinal stromal tumors (GIST), holds promise [41–43].